CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Sodium Acetate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2016-02-03. Latest FDA row update: 2026-10-01.
FDA lists 15 package records, with companies: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company, MILLA PHARMACEUTICALS INC., Milla Pharmaceuticals, Somerset Therapeutics, LLC. Package NDCs: 0409-3299-05, 0409-3299-06, 0409-3299-25, 0409-3299-26, 0409-7299-25, 0409-7299-73, 0641-6261-01, 0641-6262-01, 63323-032-00, 70069-047-25, 70069-048-20, 71357-002-10, 71357-007-10, 71357-008-10, 71357-009-10.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-032-00 | Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00) | Available | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6262-01 | Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6261-01 | Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01) | Available | 2026-09-18 |
| Hospira, Inc., a Pfizer Company | 0409-3299-05 | Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3299-26 | Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-3299-06 | Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06) | Limited Availability | 2026-08-24 |
| Hospira, Inc., a Pfizer Company | 0409-3299-25 | Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-7299-25 | Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-7299-73 | Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73) | Available | 2026-09-22 |
| Milla Pharmaceuticals | 71357-007-10 | Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10) | Available | 2026-10-01 |
| Milla Pharmaceuticals | 71357-008-10 | Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10) | Available | 2026-10-01 |
| Milla Pharmaceuticals | 71357-002-10 | Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10) | Available | 2026-10-01 |
| Milla Pharmaceuticals | 71357-009-10 | Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10) | Limited Availability | 2026-10-01 |
| Somerset Therapeutics, LLC | 70069-047-25 | Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25) | Available | 2026-09-11 |
| Somerset Therapeutics, LLC | 70069-048-20 | Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20) | Available | 2026-09-11 |
Source facts
Grouped generic ingredient: Sodium Acetate Injection · 15 package records
Therapeutic categories: Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.